|
Mar 7
|
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
|
Feb 13
|
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
|
|
Dec 6
|
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
|
|
Nov 28
|
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
|
|
Nov 1
|
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
|
|
Aug 10
|
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
|
|
May 26
|
Phathom Pharmaceuticals, Inc. (PHAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
|
|
May 25
|
Should You Buy Phathom Pharmaceuticals, Inc. (PHAT) After Golden Cross?
|
|
May 23
|
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
|
|
May 23
|
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock
|
|
May 23
|
Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
|